This Program was begun in 1999 to foster the establishment of a consortium of laboratories in the Boston- Cambridge area that shared a common interest in elucidating the molecular mechanisms of breast cancer development. The proposed Program will continue the monthly meetings and annual retreat of all researchers involved in the research sponsored by this Program. The participating groups have specific interests in various of the molecular and biological steps that cause normal human mammary epithelial cells (MECs) to develop progressively into carcinoma cells. David Livingston's research addresses the BRCA1 and allied proteins, defective forms of which are associated with the destabilization of the genome of MECs; recent research indicates that the BRCA1 gene may function in yet other ways to prevent the initiation of breast cancers. Joan Brugge's research is concentrated on characterizing the molecular mechanisms by which certain aberrantly functioning genes are able to perturb the morphogenesis of the acini in the mammary epithelium, thereby triggering some of the earliest histological abnormalities in the human breast. Mark Ewen's work is focused on understanding the molecular mechanism by which cyclin D1 -- a protein that is frequently over-expressed in human breast cancer cells -- is able to derail the normal proliferation and differentiation of human MECs. Peter Sicinski's research is directed toward understanding how mitogenic signals (normal or oncogenic) impinging on the surface of a MEC are able to communicate with the cell cycle apparatus in the nucleus of such a cell, in part by inducing expression of D-type cyclins. The work of Myles Brown addresses a similarly important attribute of many advanced breast carcinomas -- the actions of the estrogen receptor (ER) and the mechanisms through which collaborating transcriptional regulators (i.e., co-activators) are able to mediate the activating and suppressive functions of the ligandbound ER. Finally, Robert Weinberg's research is directed at three distinct areas of breast cancer development -- the reconstruction of normal breast tissue in mice, the possible role of prolactin in creating localized mammary hyperplasias, and the actions of a transcription factor in imparting the attributes of invasiveness and metastasis to already-tumorigenic MECs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA080111-07
Application #
6872947
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mohla, Suresh
Project Start
1999-03-18
Project End
2009-01-31
Budget Start
2005-02-01
Budget End
2006-01-31
Support Year
7
Fiscal Year
2005
Total Cost
$1,931,740
Indirect Cost
Name
Whitehead Institute for Biomedical Research
Department
Type
DUNS #
120989983
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Xiao, Tengfei; Li, Wei; Wang, Xiaoqing et al. (2018) Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy. Proc Natl Acad Sci U S A 115:7869-7878
Zhang, Jinfang; Bu, Xia; Wang, Haizhen et al. (2018) Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553:91-95
Li, Andrew G; Murphy, Elizabeth C; Culhane, Aedin C et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation. Proc Natl Acad Sci U S A 115:E9600-E9609
Wu, Yanming; Zhang, Zhao; Cenciarini, Mauro E et al. (2018) Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER?-GREB1 Transcriptional Axis. Cancer Res 78:671-684
Witwicki, Robert M; Ekram, Muhammad B; Qiu, Xintao et al. (2018) TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer. Cell Rep 25:1255-1267.e5
Jeselsohn, Rinath; Bergholz, Johann S; Pun, Matthew et al. (2018) Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell 33:173-186.e5
Hinohara, Kunihiko; Wu, Hua-Jun; Vigneau, Sébastien et al. (2018) KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell 34:939-953.e9
Wan, Lixin; Xu, Kexin; Wei, Yongkun et al. (2018) Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. Mol Cell 69:279-291.e5
Wang, Haizhen; Nicolay, Brandon N; Chick, Joel M et al. (2017) The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature 546:426-430
Shibue, Tsukasa; Weinberg, Robert A (2017) EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol 14:611-629

Showing the most recent 10 out of 136 publications